Terms of Service

IMPORTANT: DrugSynthAI generates computational predictions only. This platform does not provide medical advice, clinical recommendations, or therapeutic guidance. All outputs require independent experimental validation and regulatory approval. This service is not a substitute for professional medical judgment.

Effective date: 2026-03-29 · Last updated: 2026-03-29
FxMEDUS LLC · Boston, MA · Patent Pending: US Provisional Application 64/018,624

NO MEDICAL ADVICE. DrugSynthAI outputs are computational predictions generated by AI models and in silico screening pipelines. Nothing on this platform constitutes clinical, medical, or therapeutic advice. Platform outputs must not be used to make clinical decisions or guide patient care without appropriate experimental validation, regulatory review, and professional medical judgment.

1. Service Description

DrugSynthAI is an AI-governed computational drug discovery platform operated by FxMEDUS LLC. The platform provides:

AI-assisted target identification and compound generation
In silico ADMET filtering and molecular docking analysis
Reinforcement learning optimization of candidate compound scores
Governance infrastructure including stage decision records and audit trails
Export tools for CRO dispatch packages, regulatory dossiers, and thesis drafts

All outputs are computational predictions and have not been experimentally validated unless explicitly stated.

2. Acceptance of Terms

By accessing or using DrugSynthAI, you ("User") agree to be bound by these Terms of Service. If you do not agree to these terms, do not use the platform. If you are using the platform on behalf of an organization, you represent that you have authority to bind that organization to these terms.

3. Intellectual Property

Platform IP: The DrugSynthAI platform, including its AI architecture, governance infrastructure, pipeline stages, and source code, is owned by FxMEDUS LLC. The platform is covered by US Provisional Patent Application 64/018,624. Unauthorized reproduction, distribution, or reverse engineering is prohibited.

User Campaign Data: You retain full ownership of the scientific data, compound hypotheses, and research outputs generated through your campaigns on the platform. FxMEDUS LLC claims no ownership over compounds you discover or therapeutic hypotheses you generate.

License Grant: Subject to these terms, FxMEDUS LLC grants you a limited, non-exclusive, non-transferable license to access and use the platform for research purposes.

4. Acceptable Use

You agree to use DrugSynthAI only for:

Legitimate scientific and drug discovery research
Academic research and publication
Pre-clinical compound discovery programs
Educational and training purposes in drug discovery

You expressly agree NOT to use DrugSynthAI for:

Design of biological or chemical weapons
Synthesis planning for controlled substances intended for illegal manufacture
Circumventing export control regulations
Any purpose prohibited by applicable law
Systematic scraping of platform data or APIs without written permission
Uploading proprietary third-party data without proper authorization

5. Service Tiers and Limitations

Tier	Monthly Messages	Campaigns	Export Access
Explorer (Free)	25	1	Basic exports
Professional	200	5	Full exports (CRO, thesis, regulatory)
Enterprise	Custom	Unlimited	Full exports + API access

FxMEDUS LLC reserves the right to modify tier limits with 30 days advance notice to affected users.

6. Disclaimer of Warranties

THE PLATFORM IS PROVIDED "AS IS" AND "AS AVAILABLE" WITHOUT WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT.

SPECIFICALLY:

We do not warrant that computational predictions will be experimentally validated
We do not warrant that docking scores or ADMET predictions are accurate for any specific compound
We do not warrant uninterrupted or error-free service
Reinforcement learning optimization results are heuristic and not guaranteed

7. Limitation of Liability

TO THE MAXIMUM EXTENT PERMITTED BY LAW, FXMEDUS LLC SHALL NOT BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES ARISING FROM YOUR USE OF THE PLATFORM, INCLUDING BUT NOT LIMITED TO:

Failed experimental validation of computationally predicted compounds
Research delays or costs arising from reliance on platform outputs
Loss of data or campaign history
Third-party intellectual property disputes arising from platform-generated compounds

Our aggregate liability to you shall not exceed the amounts paid by you for the platform in the 12 months preceding the claim.

8. Account Responsibility

You are responsible for:

Maintaining the confidentiality of your API keys and access credentials
All activity that occurs under your account
Promptly notifying us of any unauthorized use at support@fxmedus.com
Ensuring your use complies with your employer's or institution's policies

9. Termination

Either party may terminate the service relationship with 30 days written notice. FxMEDUS LLC may terminate or suspend your access immediately without notice if you violate the Acceptable Use policy (Section 4) or these Terms.

Upon termination, you may export your campaign data via the platform API for 30 days, after which data may be deleted.

10. Export Compliance

The DrugSynthAI platform and its outputs are subject to United States export control laws and regulations, including the Export Administration Regulations (EAR). You agree to comply with all applicable export control laws. You represent that you are not located in a US-embargoed country or on any US government restricted-party list.

11. Governing Law and Dispute Resolution

These Terms are governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to its conflict of law provisions.

Any dispute arising out of or relating to these Terms or the platform shall be resolved by binding arbitration in Boston, Massachusetts under the rules of the American Arbitration Association (AAA). The arbitration shall be conducted in English. The arbitrator's decision shall be final and binding.

Notwithstanding the foregoing, either party may seek injunctive or equitable relief in any court of competent jurisdiction to protect intellectual property rights.

12. Changes to Terms

We reserve the right to modify these Terms at any time. Material changes will be communicated via the platform dashboard or email with at least 14 days advance notice. Continued use of the platform after the effective date of revised Terms constitutes acceptance.

13. Contact

FxMEDUS LLC
Boston, Massachusetts, USA
Email: support@fxmedus.com
PI: Dr. Julian Borges, MD — jyborges@bu.edu